Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vepdegestrant by Arvinas for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Vepdegestrant is under clinical development by Arvinas and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative...
Vepdegestrant by Arvinas for Metastatic Breast Cancer: Likelihood of Approval
Vepdegestrant is under clinical development by Arvinas and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase...
ARV-393 by Arvinas for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
ARV-393 is under clinical development by Arvinas and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According to...
ARV-393 by Arvinas for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
ARV-393 is under clinical development by Arvinas and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...
Vepdegestrant by Arvinas for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Vepdegestrant is under clinical development by Arvinas and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative...
Risk adjusted net present value: What is the current valuation of Arvinas's Bavdegalutamide?
Bavdegalutamide is a small molecule commercialized by Arvinas, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer (mCRPC)....